Aptar Adds Nasal Pump Manufacturing Capacity
PTSM: Pharmaceutical Technology Sourcing and Management
Aptar now manufactures its child-resistant pump, designed to meet US CPC requirements, at its facility in Congers, New York.
Aptar Pharma transferred equipment to manufacture its Child-Resistant and Senior-Friendly Classic Nasal Pump from its plant in southern Germany to its Congers, New York site, the company announced on June 12, 2017. The move, which took place in April 2017, brought manufacturing capacity closer to the US target market for the pump. The child-resistant technology was developed primarily for the US market when, in 2012, the US Consumer Product Safety Commission issued a rule requiring child-resistant packaging for any over-the-counter or drug product containing the equivalent of 0.08 mg or more of imidazoline, a formulation widely used in nasal decongestant topical sprays.
The company had also expanded manufacturing capacity at the Congers site for injection molding of elastomeric components, such as stoppers for parenteral containers, in March 2017.
Source: Aptar Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
